Literature DB >> 9142565

Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma.

U V Singh1, N Udupa.   

Abstract

Inclusion complex of plumbagin was prepared with betacyclodextrin employing neutralization method. The toxicity of the drug was reduced and the antitumor efficacy was enhanced on complexation with betacyclodextrin.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9142565

Source DB:  PubMed          Journal:  Indian J Physiol Pharmacol        ISSN： 0019-5499


  10 in total

Review 1.  Chemical biology of histone acetyltransferase natural compounds modulators.

Authors:  Fabrizio Dal Piaz; Antonio Vassallo; Osmany Cuesta Rubio; Sabrina Castellano; Gianluca Sbardella; Nunziatina De Tommasi
Journal:  Mol Divers       Date:  2011-01-01       Impact factor: 2.943

2.  Plumbagin inhibits proliferative and inflammatory responses of T cells independent of ROS generation but by modulating intracellular thiols.

Authors:  Rahul Checker; Deepak Sharma; Santosh K Sandur; G Subrahmanyam; Sunil Krishnan; T B Poduval; K B Sainis
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

3.  Identification of a molecular activator for insulin receptor with potent anti-diabetic effects.

Authors:  Kunyan He; Chi-Bun Chan; Xia Liu; Yonghui Jia; Hongbo R Luo; Stefan A France; Yang Liu; W David Wilson; Keqiang Ye
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

4.  The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2.

Authors:  Suneet Shukla; Chung-Pu Wu; Krishnamachary Nandigama; Suresh V Ambudkar
Journal:  Mol Cancer Ther       Date:  2007-12-07       Impact factor: 6.261

5.  5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization.

Authors:  Santosh K Sandur; Manoj K Pandey; Bokyung Sung; Bharat B Aggarwal
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

6.  Plumbagin shows anticancer activity in human osteosarcoma (MG-63) cells via the inhibition of S-Phase checkpoints and down-regulation of c-myc.

Authors:  Chao-Hua Yan; Feng Li; Yuan-Chen Ma
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin.

Authors:  Wiriyaporn Sumsakul; Tullayakorn Plengsuriyakarn; Kesara Na-Bangchang
Journal:  BMC Pharmacol Toxicol       Date:  2016-11-14       Impact factor: 2.483

8.  Molecular Dynamic Simulation Analysis on the Inclusion Complexation of Plumbagin with β-Cyclodextrin Derivatives in Aqueous Solution.

Authors:  Kulpavee Jitapunkul; Pisanu Toochinda; Luckhana Lawtrakul
Journal:  Molecules       Date:  2021-11-10       Impact factor: 4.411

9.  Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approaches.

Authors:  Mohammad S Jamal; Shadma Parveen; Mohd A Beg; Mohd Suhail; Adeel G A Chaudhary; Ghazi A Damanhouri; Adel M Abuzenadah; Mohd Rehan
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

10.  Host-Guest Interactions of Plumbagin with β-Cyclodextrin, Dimethyl-β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin: Semi-Empirical Quantum Mechanical PM6 and PM7 Methods.

Authors:  Ornin Srihakulung; Ryo Maezono; Pisanu Toochinda; Waree Kongprawechnon; Apichart Intarapanich; And Luckhana Lawtrakul
Journal:  Sci Pharm       Date:  2018-05-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.